This genetic study identified a potential interval for the Marie Unna hypotrichosis gene but found no mutations in the nearby hr gene, suggesting its involvement remains unconfirmed.
93 citations
,
April 2003 in “Proceedings of the National Academy of Sciences of the United States of America”
This study identified an unexpected critical role for the FATP4 protein in skin and hair development in mice, linking it to a potential candidate gene for restrictive dermopathy in humans.
This study found that poly(butylene citramalate-co-butylene succinate) copolymers exhibit high toughness, recyclability, degradability, and biocompatibility, achieving complete wound healing with skin and hair follicle regeneration in 7 days.
This study presents the first report on cloning and characterizing the full-length cDNA of SRD5A1 in Indian catfish (Clarias magur), revealing expression differences across reproductive phases and increased expression post-Ovatide administration in ovaries and testis.
Creatine may counteract minoxidil's hair growth effects by closing potassium ATP channels, potentially leading to hair loss in predisposed individuals. Despite anecdotal reports, there is no conclusive evidence linking creatine to hair loss.
New hair loss treatments like GT20029 and PP405 could potentially replace minoxidil and finasteride, offering better results with fewer side effects. However, current treatments like finasteride and minoxidil are still effective for many, despite concerns about side effects.
A 36-year-old man shared his 1.25-year progress using oral finasteride, oral minoxidil, RU58841, microneedling, nizoral, and LLLT for hair regrowth. He is thrilled with the results and considering a hair transplant for increased density.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.